Waterloo Capital’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$956K Buy
34,043
+7,882
+30% +$210K 0.07% 214
2025
Q4
$651K Buy
26,161
+1,377
+6% +$34.7K 0.05% 258
2025
Q3
$632K Buy
24,784
+7,243
+41% +$179K 0.05% 237
2025
Q2
$425K Buy
17,541
+2,499
+17% +$58.3K 0.03% 299
2025
Q1
$381K Buy
15,042
+405
+3% +$10.6K 0.04% 288
2024
Q4
$388K Sell
14,637
-3,930
-21% -$107K 0.04% 265
2024
Q3
$537K Sell
18,567
-1,665
-8% -$48.6K 0.06% 224
2024
Q2
$566K Sell
20,232
-41,162
-67% -$1.13M 0.07% 205
2024
Q1
$1.7M Buy
61,394
+15,046
+32% +$418K 0.22% 103
2023
Q4
$1.33M Buy
+46,348
New +$1.4M 0.22% 108

Other funds holding PFE

Waterloo Capital's PFE Position: Q1 2026 in Review

Waterloo Capital increased its Pfizer (PFE) stake by 30% in Q1 2026, buying an estimated $210K and bringing the position to 34,043 shares worth $956K. The position accounts for 0.07% of the portfolio, ranked #214.

Waterloo Capital first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.7M in Q1 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Waterloo Capital held 34,043 shares of Pfizer worth $956K as of Q1 2026.
  • Waterloo Capital bought 7,882 Pfizer shares in Q1 2026, an estimated $210K.
  • Pfizer made up 0.07% of Waterloo Capital's portfolio in Q1 2026, its #214 holding.
  • Waterloo Capital first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • Waterloo Capital's Pfizer position peaked at $1.7M in Q1 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Waterloo Capital's 13F filing for Q1 2026, filed 12 May 2026.